- To develop directly substitutable, generic mono- and combination therapies for asthma and COPD, utilising where possible regulatory guidelines for accelerated approval (e.g. by in vitro equivalence route in Europe).
- To develop ‘super-generic’ (novel) versions of generic mono- and combination therapies for asthma and COPD using simple, cost effective already approved devices.
- To develop the next generation of combination respiratory medicines based on its unique Multi-component Particles™ (MCP™). MCPs™ consist of two or more respiratory drugs combined consistently in a pre-determined ratio in each and every particle in the formulation. They offer the potential to eliminate the dose variability that comes from the classical physical blending of two drugs in existing combination therapies and to ensure co-association and co-localisation of both drugs at the target site with the intention of producing an enhanced synergistic clinical effect.
Prosonix aims to leverage its technology and expertise to develop its own drug development programmes rapidly to the optimal point for securing high-value licensing deals with pharmaceutical, speciality pharma or generics companies, thereby generating significant value for its shareholders.
In addition, Prosonix has established a number of co-development partnerships with companies focused on the development of inhaled drugs for respiratory and other indications.